Cell-specific barcodes attach an identifying label to the complementary DNA generated from each cell’s captured RNA. During sequencing, those labels allow reads to be assigned back to their originating cells rather than combined into one sample-wide measurement. This assignment preserves cell-to-cell differences and produces separate transcriptomic profiles for downstream interpretation.
Bulk analysis averages RNA signals across all cells in a specimen, which can conceal smaller or biologically distinct populations. Single-cell measurements retain those differences, making it possible to examine separate tumor, immune, and stromal profiles. This resolution helps expose heterogeneity and identify gene-expression programs associated with progression or treatment resistance.
Comparing transcriptomic profiles across individual cells can separate malignant cells from immune and stromal populations within the same cancer sample. The resulting cellular identities and states show whether a gene-expression pattern belongs to tumor cells or to neighboring components of the tumor environment. This distinction strengthens interpretation of disease-associated signals and potential biomarkers.
The workflow begins by isolating cells from a sample and capturing RNA from individual cells. The captured RNA is then converted into complementary DNA, or cDNA, while cell-specific barcodes are incorporated. After sequencing, reads are assigned to their labeled cells to generate transcriptomic profiles that can be compared across the sample.
Single-cell transcriptomic profiles can reveal which cell populations are present and describe their molecular states. In cancer research, they help identify tumor heterogeneity and gene-expression programs linked to disease progression or treatment resistance. Because the measurements retain cellular context, researchers can connect particular expression patterns with malignant, immune, or stromal populations.
The profiles can reveal expression patterns associated with specific cellular populations, disease progression, or resistance to treatment. Researchers can use those patterns to support biomarker discovery and patient stratification, grouping patients according to relevant molecular features. The same information may guide more precisely targeted therapies by identifying cellular states that require focused intervention.